

Haematologica  
HAEMATOL/2020/257048  
Version 1

A step ahead toward precision medicine for chronic lymphocytic  
leukemia

Andrea Patriarca and Gianluca Gaidano

Disclosures: AP and GG have no conflicts of interest to disclose for the work under consideration. Outside of the submitted work, AP declares fees from Sanofi and Takeda for Advisory Boards; GG declares fees from Janssen, Abbvie, Sunesys and Astra-Zeneca for Advisory Boards and Speaker's Bureau.

Contributions: Andrea Patriarca and Gianluca Gaidano wrote the Editorial together and provided final approval of the submitted version.